Helixmith Co., Ltd (084990.KQ) KOE
Currency In KRW
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In KRW
Address
Building 203
Seoul, 151-747
Korea (the Republic of)
Phone
82 2 2102 7200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
132
First IPO Date
December 29, 2005
| Name | Title | Pay | Year Born |
| Sunyoung Kim | Founder, Chief Executive Officer & Director | 0 | 1955 |
| Won Park | Pres | 0 | N/A |
| Jong-Mook Kim | Director of Devel. Division & Strategic Bus. Division and Director | 0 | 1972 |
| Jun Tae Park | Executive Vice President of Licensing & Regulatory Affairs | 0 | N/A |
| Miwon Son | Senior Managing Director of Phytotherapeutics | 0 | N/A |
| Michael Na | Chief Financial Officer & Director of Office of Strategic Net Assessment | 0 | N/A |
| William O. Frank | Head of Medical | 0 | N/A |
| Seung-Shin Yu | Chief Technology Officer , Representative Director, MD of R&D Center and Intellectual Property & Director | 0 | 1966 |
Helixmith Co., Ltd is a biotechnology enterprise focused on discovering and advancing novel biopharmaceutical solutions for human diseases. The company maintains a comprehensive pipeline of innovative biologics and herbal therapies, addressing therapeutic areas like cardiovascular ailments, cancer, and immune system disorders. Its clinical research activities are actively conducted across the United States, South Korea, and China. A cornerstone of its product portfolio is VM202, a groundbreaking DNA-based drug designed for treating both cardiovascular and neurological conditions. Additionally, Helixmith's developmental compounds include VM206, a therapeutic vaccine targeting HER2/neu positive breast or ovarian cancer, and VM501, a re-engineered variant of interleukin 11 aimed at alleviating chemotherapy-induced thrombocytopenia. Its ongoing clinical trials encompass VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. Founded in 1996, the company adopted the name Helixmith Co., Ltd in April 2019, transitioning from its former identity as ViroMed Co., Ltd. The organization's main office is located in Seoul, South Korea.